Samsung Biologics hits W3tr in cumulative orders this year
According to a regulatory filing, the company recently signed two new contract manufacturing organization, or CMO, deals totaling 440.5 billion won with pharmaceutical companies based in Europe and Asia.
These contracts run through December 2030 and December 2033, respectively. Due to non-disclosure agreements, client names and product details were not disclosed.
So far in 2025, Samsung Biologics has signed four CMO deals across the US, Europe and Asia. This achievement represents over 60 percent of its total contract value for 2024, reinforcing the company's global competitiveness.
The company now counts 17 of the world's top 20 pharmaceutical companies as clients and has accumulated total orders of approximately $18.2 billion since its founding.
With the recent launch of its fifth plant in April, adding 180,000 liters of capacity, Samsung Biologics has expanded its total capacity to 784,000 liters, the largest in the world.
Samsung Biologics also maintains strong performance in quality control, recording a 99 percent batch success rate last year and securing 356 manufacturing approvals from global regulators as of April 2025.
To expand its global presence, the company has actively participated in major industry events including JPMorgan Healthcare Conference, DCAT Week 2025 and PEGS Boston.
Samsung Biologics will next join the BIO International Convention held in Boston this June to further strengthen its global partnerships.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
6 days ago
- Korea Herald
AMI Pharm Advances AYP-101 to Phase 3, Paving the Way for a New Era in Fat-Reduction Injectable drugs
— Novel non-cytolytic injectable drug targets submental fat with significantly reduced pain and swelling — Phase 3 clinical trial underway in South Korea, following strong safety and efficacy results in earlier studies — AMI Pharm positions itself for global expansion in the multi-billion-dollar non-surgical aesthetics market SEOUL, South Korea, Aug. 11, 2025 /PRNewswire/ -- AMI Pharm, a biotechnology company specializing in next-generation aesthetic solutions, today announced that its lead drug candidate, AYP-101, has entered a pivotal Phase 3 clinical trial for the treatment of submental fat (commonly known as a "double chin"). This innovative injectable drug is designed to dramatically improve patient comfort by utilizing a novel biological mechanism that minimizes the pain and swelling commonly associated with existing treatments. A Paradigm Shift in Fat Reduction Therapy Currently, the only FDA-approved drug for localized fat reduction is based on deoxycholic acid, which destroys fat cells through necrosis —a process that induces inflammation and leads to significant side effects such as pain, bruising, and prolonged swelling. In contrast, AYP-101 is uniquely engineered to eliminate fat through apoptosis, a natural and controlled form of programmed cell death that does not trigger inflammation. This non-cytolytic mechanism offers a gentler, more tolerable alternative, potentially eliminating the need for social downtime and offering a safer, more comfortable experience for patients seeking non-surgical fat reduction. Phase 3 Trial Underway Following Strong Early Results The ongoing Phase 3 clinical trial involves 252 participants across multiple sites in South Korea and is expected to be completed by the end of 2025. The study builds on successful Phase 1 and 2 trials, which met all primary safety and efficacy endpoints. In the Phase 2 trial, over 70% of patients in the AYP-101 group achieved at least a 1-grade improvement on the Evaluator-Reported Submental Fat Rating Scale (ER-SMFRS) in the per-protocol (PP) population. The treatment also showed excellent tolerability and safety, with minimal adverse events reported. "AYP-101 represents the culmination of two decades of dedicated research aimed at creating a safe, effective, and globally competitive solution for localized fat reduction," said Ki-Taek Lee, CEO of AMI Pharm. "By leveraging a novel mechanism of action, we are pioneering the next generation of injectable drugs in aesthetic medicine." Targeting Global Expansion and Broader Indications AMI Pharm is actively preparing for global commercialization. The company is engaging international partners and showcasing its clinical data at world-renowned conferences, including the BIO International Convention and the IMCAS World Congress. While the current clinical focus is on submental fat, AMI Pharm is laying the groundwork to expand AYP-101's indications to address other high-demand aesthetic areas, including cellulite, deep buccal (cheek) fat, and upper arm fat. This broader R&D strategy highlights the company's commitment to addressing a wide spectrum of unmet needs in the aesthetic space and reinforces its ambition to become a global leader in non-surgical body contouring.
Korea Herald
23-07-2025
- Korea Herald
Samsung Biologics reports second quarter 2025 financial results
INCHEON, South Korea, July 23, 2025 /PRNewswire/ -- Samsung Biologics (KRX: a leading contract development and manufacturing organization (CDMO), today announced its financial results for the second quarter of fiscal year 2025. "Our second quarter results demonstrate continued strong momentum across our business," said John Rim, CEO and President of Samsung Biologics. "With Plant 5 now fully operational, we are leveraging our manufacturing expertise and expanded capacity to deliver seamless, end-to-end CDMO services at scale. We have broadened our portfolio with advancements in antibody-drug conjugates (ADCs) and the launch of research services, Samsung Organoids, further reinforcing our ability to offer a wider range of innovative solutions to clients. Additionally, we are redefining digitalization in biomanufacturing, harnessing advanced digital tools to deliver greater transparency, speed, and value—setting new standards in the industry. These strategic initiatives will continue to strengthen our ability to accelerate client pipelines, while fostering enduring partnerships grounded in quality and operational excellence." SECOND QUARTER 2025 RESULTS Samsung Biologics posted consolidated revenue of KRW 1,289.9 billion and operating profit of KRW 475.6 billion in the second quarter of 2025. On a standalone basis, the company reported revenue of KRW 1,014.2 billion and operating profit of KRW 477.0 billion. The growth was buoyed by the full utilization of Plants 1 through 3 and the continued ramp-up of Plant 4. In the first half of 2025, standalone revenue surpassed KRW 2 trillion, reflecting consistent momentum across all manufacturing plants. Sales contract volume in the first half reached USD 2.4 billion, bringing up the cumulative value to USD 18.7 billion. BUSINESS UPDATES In April, Samsung Biologics added 180 kL of capacity with Plant 5 to better meet clients' manufacturing needs. The facility, equipped with advanced automation and digital systems, integrates best practices and features from existing plants to ensure consistent operations and the highest quality standards. The company also broadened its service offering with the launch of research services, Samsung Organoids, which utilizes patient-derived organoids to support drug discovery and development. Samsung Organoids enables precision screening to predict patient-specific drug responses and provides clients with multi-modal insights to effectively support early-stage decision making. In May, Samsung Biologics announced plans to spin off its wholly-owned subsidiary, Samsung Bioepis. Through the financial and legal separation, the company will focus on strengthening its core capabilities as a pure-play CDMO, enhancing customer satisfaction and proactively responding to the industry's greater demands to ultimately maximize corporate value and sustainable growth potential. On the sustainability front, the company released its 2025 ESG report in June, outlining progress in areas including enhanced disclosure standards, an accelerated path to net-zero, and TNFD-aligned risk management. As part of its decarbonization efforts, Samsung Biologics achieved a 24% reduction in greenhouse gas emissions in 2024 compared to the previous year and increased its renewable energy use to 29% of total electricity consumption. The company also signed an additional solar Power Purchase Agreement to further support its energy transition. Beyond operations, Samsung Biologics is actively engaged in collaborative efforts through the Sustainable Market Initiative to decarbonize healthcare supply chains and promote global environmental responsibility. About Samsung Biologics Samsung Biologics (KRX: is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing. With a combined biomanufacturing capacity of 784 kL across five plants, Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. Samsung Biologics operates a global network with facilities and offices in Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality products, as well as making sustainable business decisions for the betterment of society and global health.
Korea Herald
11-07-2025
- Korea Herald
Samyang's hot streak: Global Buldak craze sends stock to record high
Shares of Samyang Foods topped the 1.5 million won ($1,090) mark, rising nearly 50 percent in just two months, as investors bet on the enduring global popularity of its hot chicken noodles, Buldak. On Thursday, the stock hit an intraday high of 1,502,000 won before closing at 1,494,000 won on the benchmark Kospi. It opened at 1,503,000 won on Friday and briefly notched a new all-time high of 1,535,000 won. As of 11 a.m. Friday, shares had eased to 1,470,000 won. The rally extends a blistering run for Samyang, which passed the 1 million won mark on May 12, a milestone that places the food maker alongside Samsung Biologics as a company with seven-figure share prices. Analysts credit the surge to expectations of strong quarterly earnings and increased production capacity. "The company's new facility will drive earnings growth as Buldak production scales up exports to the US and Europe from the third quarter," an analyst from Korea Investment & Securities noted. Sales growth was limited in the first quarter due to supply constraints in the US and Europe, the analyst added, suggesting a sharp pickup ahead. In June, Samyang's new plant in Miryang, South Gyeongsang Province, came online to supply the US and European markets. The noodle maker currently produces all of its products in Korea but is building its first overseas plant in China, slated for completion in 2027. A Kyobo Securities analyst also offered an upbeat outlook: 'Given Samyang's strong global recognition, there appears to be ample room for further upward revisions in its valuation.' Last year, Samyang's annual sales rose 45 percent to 1.73 trillion won, with operating profit soaring 133 percent to 344.2 billion won. Overseas sales reached a record 1.33 trillion won, making up nearly 80 percent of total revenue. In the US, sales doubled to $280 million; sales in China surged 75 percent to $290 million. According to financial information provider FN Guide, Samyang Foods' operating profit for the first half of this year is projected to jump 55.4 percent on-year to 263.5 billion won, with revenue projected to rise 32.2 percent to 1.07 trillion won.
